The latest price target for AlloVir (NASDAQ:ALVR) was reported by Morgan Stanley on January 5, 2024. The analyst firm set a price target for $0.50 expecting ALVR to fall to within 12 months (a possible -94.71% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for AlloVir (NASDAQ:ALVR) was provided by Morgan Stanley, and AlloVir downgraded their underweight rating.

There is no last upgrade for AlloVir

The last downgrade for AlloVir Inc happened on January 5, 2024 when Morgan Stanley changed their price target from $1 to $0.5 for AlloVir Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on January 5, 2024 so you should expect the next rating to be made available sometime around January 5, 2025.

While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a downgraded with a price target of $1.00 to $0.50. The current price AlloVir (ALVR) is trading at is $9.45, which is out of the analyst’s predicted range.